Kerala Ayurveda Ltd. (KERALAYUR) — Tipsheet

Kerala Ayurveda targets ₹200 cr revenue by FY27

Tipsheet Editorial — Mon, 25 May 2026 21:02:43 GMT

The nano-cap firm aims for 38% growth, banking on a 130% surge in e-products and a path to operating breakeven by January 2027.

What’s new

Management targets ₹200 cr revenue for FY27.
Operating breakeven is set for January 2027.
Standalone revenue crossed ₹100 cr for the first time in FY26.

Why it matters

The guidance is ambitious for a company with a market cap of ₹275 cr. Achieving this target would mean generating revenue equivalent to 73% of its current market valuation, making the execution of its e-product and health services strategy the primary test for investors.

What we’re watching

Progress on the delayed capital funding closure.
Quarterly updates on the 130% e-product growth target.
Cost-control measures as the company nears the January 2027 breakeven goal.

The full read

Kerala Ayurveda is setting a high bar for its ₹275 crore market cap. Management has issued FY27 revenue guidance of ₹200 crore, a 38% jump over the ₹145.4 crore reported in FY26. The company is betting on a 130% surge in its global e-product business and a 45% expansion in health services to get there. It also plans to hit operating breakeven by January 2027. While the standalone business recently crossed the ₹100 crore revenue threshold for the first time, the scale of this new target is significant—it represents roughly 73% of the company's current total market value. A delay in capital funding closure adds a layer of friction to these plans. Investors now have a concrete framework to track, but the gap between current operations and the ₹200 crore target is wide. The next few quarters will determine if this growth is realistic or merely aspirational.

Primary source: BSE · NSE

Kerala Ayurveda's losses widened even as revenue grew

Tipsheet Editorial — Mon, 25 May 2026 20:07:56 GMT

Standalone net loss hit ₹14.74 cr on 17.6% revenue growth; consolidated loss was ₹20.65 cr. The auditor flagged unprovided receivables from subsidiaries.

What’s new

Standalone net loss widened to ₹14.74 cr on revenue of ₹85.48 cr.
Consolidated revenue grew 9% to ₹131.15 cr but net loss was ₹20.65 cr.
Auditor flagged significant receivables from subsidiaries with no provision.

Why it matters

Revenue growth that doesn't translate to profit is a familiar problem, but the auditor's emphasis on unprovided subsidiary receivables adds a governance question to the usual operational one. The company is growing the top line but not converting it into earnings.

What we’re watching

How management addresses the auditor's receivable concern.
Whether the subsidiary receivables get provisioned in coming quarters.
Path to profitability after another year of widening losses.

The full read

Kerala Ayurveda grew standalone revenue 17.6% to ₹85.48 crore in FY26, but the ₹14.74 crore net loss was wider than the prior year. The consolidated picture is similar: 9% revenue growth to ₹131.15 crore with a net loss of ₹20.65 crore. The auditor's report adds a wrinkle, flagging significant receivables from subsidiaries with no provision set aside. That is the number to watch. Growing revenue while losing more money is one thing; doing it while your own subsidiaries owe you unprovided balances is another. The filing is a routine annual disclosure, but the auditor's emphasis gives the market a specific governance question to digest.

Primary source: BSE · NSE

Kerala Ayurveda's losses widen even as revenue climbs

Tipsheet Editorial — Mon, 25 May 2026 20:02:58 GMT

Standalone revenue grew 17.6% to ₹85.48 cr, but the net loss deepened to ₹14.74 cr. The auditor flagged unprovided subsidiary receivables.

What’s new

Standalone revenue grew 17.6% to ₹85.48 cr but the net loss widened to ₹14.74 cr.
Consolidated revenue rose 9% to ₹131.15 cr with a consolidated net loss of ₹20.65 cr.
Audit report contained an emphasis of matter on significant unprovided trade receivables from subsidiaries.

Why it matters

Kerala Ayurveda is adding revenue but losing more money doing it. The standalone loss grew even faster than the topline. The auditor's flag on subsidiary receivables without provision means a portion of the balance sheet may not be collectible, adding an asset-quality question to the operating losses.

What we’re watching

Whether management discloses a plan to collect or write down the flagged subsidiary receivables.
If the consolidated loss trajectory stabilises as standalone revenue scales.
Any capital raise to shore up the balance sheet after a loss year.

The full read

Kerala Ayurveda's FY25-26 results show a company adding revenue but deepening losses. Standalone revenue rose 17.6% to ₹85.48 cr, yet the net loss widened to ₹14.74 cr. Costs are growing faster than sales. On a consolidated basis, revenue grew 9% to ₹131.15 cr with a total loss of ₹20.65 cr, meaning subsidiaries are also in the red. The auditor's emphasis on significant, unprovided trade receivables from those subsidiaries is the other problem. A chunk of the company's reported assets may not be collectible. This was a routine annual disclosure, but rising losses paired with an auditor flag on asset quality is the kind of result that demands a clear management answer.

Primary source: BSE · NSE

Kerala Ayurveda's losses widen even as top line grows

Tipsheet Editorial — Mon, 25 May 2026 19:46:12 GMT

Audited results for FY26 show standalone revenue up 17.6% but net loss deepening. The auditor flagged unprovided receivables from subsidiaries.

What’s new

Standalone revenue grew 17.6% to ₹85.48 cr but net loss widened to ₹14.74 cr.
Consolidated revenue rose 9% to ₹131.15 cr; consolidated net loss hit ₹20.65 cr.
Audit report includes an emphasis of matter on significant trade receivables from subsidiaries with no provision made.

Why it matters

Top-line growth without operating profit is the core problem. The wider loss despite a nearly 18% revenue jump means cost pressures are outpacing sales gains. The auditor's flag on unprovided subsidiary receivables adds a governance question to the financial one.

What we’re watching

Whether the receivable issue triggers further scrutiny or a write-down.
Any management commentary on the path to profitability.
How the consolidated loss compares to prior-year consolidated figures.

The full read

Kerala Ayurveda grew revenue but kept losing money. Standalone sales for FY26 rose 17.6% to ₹85.48 crore, yet the net loss widened to ₹14.74 crore from ₹13.78 crore the year before. Consolidated results told the same story: 9% revenue growth to ₹131.15 crore against a deeper net loss of ₹20.65 crore. The audit report adds a governance wrinkle. It contains an emphasis of matter on significant trade receivables from subsidiaries with no provision made, meaning the company has not reserved against potential non-collection. This is a routine annual filing, but the numbers underline a persistent gap between growth and profitability.

Primary source: BSE · NSE